Medivir AB (MVIRb.F) Announces Interim Results From Cohort 2 of the COSMOS Study Evaluating Simeprevir and Sofosbuvir in HCV Patients With METAVIR Scores F3-F4
8/28/2013 9:33:35 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced interim results from
the second Cohort in the ongoing COSMOS study evaluating a once daily
combination of simeprevir and sofosbuvir in hard to cure hepatitis C (HCV)
Help employers find you! Check out all the jobs and post your resume.
comments powered by